Overview

A Pilot Surgical Trial To Evaluate Early Immunologic Pharmacodynamic Parameters For The PD-1 Checkpoint Inhibitor, Pembrolizumab (MK-3475), In Patients With Surgically Accessible Recurrent/Progressive Glioblastoma

Status:
Completed
Trial end date:
2021-10-01
Target enrollment:
Participant gender:
Summary
This research study is studying an immunotherapy as a possible treatment for Glioblastoma.
Phase:
Phase 1
Details
Lead Sponsor:
Dana-Farber Cancer Institute
Collaborator:
Merck Sharp & Dohme Corp.
Treatments:
Pembrolizumab